Table 1. Specifications and concentrations of the estrogen receptor (ER) agonists and antagonists applied to trigeminal ganglia neuron primary cultures.

E2-BSA: β-Estradiol 6-(O-carboxymethyl)oxime conjugated to bovine serum albumin (BSA); G-1: rel-1-[4-(6-bromo-1,3-benzodioxol-5-yl)-3aR,4S,5,9bS-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-ethanone; ICI 182,780: 7α,17β-[9-[(4,4,5,5,5 Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol; PPT: 1,3,5-Tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole; DPN: 2,3-Bis(4-hydroxyphenyl)propionitrile; MPP: MPP Dihydrochloride; PHTPP: 4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]-pyrimidin-3-yl]phenol.

Pharmacologic	Target	Company	Cat. #	Concentration	Ref.
E2-BSA	Membrane-impermeable E2	Sigma–Aldrich	E5630	50 nM	[95]
G-1	GPER agonist	Cayman Chemical	10008933	10 nM	[15; 93]
ICI 182,780	ER antagonist; GPER agonist	Sigma–Aldrich	5310420001	1 μM	[96]
PPT	ERα agonist	Sigma–Aldrich	H6036	100 nM	[21; 62; 96]
DPN	ERβ agonist	Sigma–Aldrich	H5915	15 nM	[21; 78; 96; 116]
MPP	ERα antagonist	Sigma–Aldrich	M7068	300 nM	[96; 107]
PHTPP	ERβ antagonist	Sigma–Aldrich	SML1355	1 μM	[21; 60]